For acutely decompensated heart failure patients, UCN2 infusion leads to decreased systolic blood pressure, a reduction in total peripheral resistance, and increased cardiac output with a nonsignificant elevation in heart rate when compared to the placebo group [88]. The gene discussed is UCN2; the disease is heart failure.